论文部分内容阅读
目的探讨环氧合酶-2(COX-2)、血管内皮生长因子-C(VEGF-C)和血管内皮生长因子受体3(VEGFR-3)在卵巢癌组织中的表达及其临床意义。方法采用免疫组织化学方法检测卵巢上皮性癌组织98例和卵巢良性上皮性肿瘤组织30例中COX-2、VEGF-C及VEGFR-3蛋白的表达。结果卵巢上皮性癌中COX-2、VEGF-C和VEGFR-3蛋白的阳性表达率均明显高于良性上皮性肿瘤(P<0.05),三者在卵巢上皮性癌组织Ⅲ、Ⅳ中的表达率明显高于Ⅰ、Ⅱ期,随着病理分级增高而显著增加(P<0.05)。结论COX-2、VEGF-C及其受体VEGFR-3蛋白在卵巢癌组织中不同程度异常表达与肿瘤的临床分期、病理分级均有密切关系,通过检测COX-2、VEGF-C及其受体VEGFR-3蛋白的表达有助于预测卵巢癌患者的预后。
Objective To investigate the expression of cyclooxygenase-2 (COX-2), vascular endothelial growth factor-C (VEGF-C) and vascular endothelial growth factor receptor 3 (VEGFR-3) in ovarian cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of COX-2, VEGF-C and VEGFR-3 in 98 cases of ovarian epithelial carcinoma and 30 cases of ovarian benign epithelial tumor. Results The positive rates of COX-2, VEGF-C and VEGFR-3 protein in epithelial ovarian cancer were significantly higher than those in benign epithelial tumors (P <0.05). The expressions of COX-2, VEGF- The rates were significantly higher than those in stage Ⅰ and Ⅱ, with the pathological grade increased significantly (P <0.05). Conclusions The abnormal expression of COX-2, VEGF-C and their receptor VEGFR-3 in ovarian cancer tissues is closely related to the clinical stage and pathological grade of the tumor. By detecting the expression of COX-2, VEGF-C and its receptor The expression of VEGFR-3 protein helps predict the prognosis of patients with ovarian cancer.